Voyager Therapeutics is trading at $2.05, down 6.40% in pre-market; no confirmed catalyst for the move was identified. - On October 21, Voyager Therapeutics announced a leadership succession plan: Robin Swartz became President and is expected to succeed CEO Alfred Sandrock in Q1 2027, after initial VY1706 safety data. The announcement does not link the transition to the share-price decline. - Biotech’s pre-market gain of 3.64% contrasts with the stock’s decline, so sector strength does not explain the move.